Zentek signs MOU with Al-Ramez International Group

Zentek (ZTEK) has signed a Memorandum of Understanding with Al-Ramez International Group, through Saudi Excellence Holding Company, establishing a strategic partnership to drive innovation and commercialization in advanced technologies across the Kingdom of Saudi Arabia and the Middle East and North Africa region on November 14 2024. The MOU outlines a collaborative framework where Zentek intends to contribute intellectual property, product licensing, and research and development expertise, whileAl-Ramez International Group intends to provide marketing support, investor relations, financing, and access to the KSA and MENA market. Together, the parties aim to achieve several key objectives: Graphene Production Hub: Develop a world-class graphene production facility in the KSA focusing on ZenGUARD technologies for distribution in the KSA and across the MENA region. Commercialization Hub: Establish a centralized hub for the commercialization of Zentek’s current and future graphene technologies. Biotechnology Expansion: Support local research and production initiatives by advancing and commercializing Triera Biosciences multivalent aptamer technology for rapid drug discovery within the KSA and MENA region. Strategic Investment in Resources: Facilitate investment and development of the Albany Graphite Deposit to support the North American supply chain for advanced materials, including anode material for the electric vehicle market. Aptamer Research and Development: Secure funding for Triera to establish and expand aptamer research and development in conjunction with a Saudi university and private sector partners and build a production facility for the KSA and MENA region. This MOU, a direct result of the groundwork laid during trips to the United Arab Emirates and Saudi Arabia, reflects the shared vision of fostering advanced, efficient, and affordable solutions to meet the needs of industries and institutions across the region. The potential partnership also considers exclusivity and joint ventures related to the Company’s opportunities that may also position Al-Ramez International Group as a key equity partner. The Company believes this potential partnership could be a significant step toward successfully commercializing many of its opportunities and creating benefits for both parties. To support these and other international business opportunities, the Company has applied for and been accepted into the World Trade Centre Toronto’s Trade Accelerator Program Life Sciences Commercialization for Global Success. The TAP program focuses on the following areas: Understanding key concepts in medical technology commercialization for international markets; Ensuring products meet healthcare needs while demonstrating clear value; Validating target markets and creating a comprehensive export plan to guide global commercialization efforts; Establishing profitable entities that serve both local and global customer bases.